Victory Capital Management
CLVS

Victory Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Victory Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-16,075
Closed -$19K – 2760
2022
Q3 		$19K Sell
16,075
-2,925
-15% -$4.56K ﹤0.01% 2634
2022
Q2 		$34K Buy
19,000
+88
+0.5% +$130 ﹤0.01% 2583
2022
Q1 		$38K Buy
18,912
+1,138
+6% +$2.23K ﹤0.01% 2614
2021
Q4 		$48K Buy
17,774
+1,078
+6% +$3.98K ﹤0.01% 2644
2021
Q3 		$74K Buy
16,696
+1,372
+9% +$6.61K ﹤0.01% 2655
2021
Q2 		$89K Sell
15,324
-640
-4% -$3.75K ﹤0.01% 2612
2021
Q1 		$112K Buy
15,964
+2,056
+15% +$13.8K ﹤0.01% 2590
2020
Q4 		$67K Buy
13,908
+728
+6% +$3.68K ﹤0.01% 2442
2020
Q3 		$77K Buy
13,180
+161
+1% +$963 ﹤0.01% 2360
2020
Q2 		$88K Buy
13,019
+2,077
+19% +$15.7K ﹤0.01% 2367
2020
Q1 		$70K Buy
+10,942
New +$87.8K ﹤0.01% 2420
2019
Q4 		– Sell
-8,876
Closed -$35K – 3514
2019
Q3 		$35K Buy
+8,876
New +$71.8K ﹤0.01% 2844
2018
Q3 		– Sell
-189
Closed -$9K – 1916
2018
Q2 		$9K Sell
189
-14,440
-99% -$702K ﹤0.01% 1812
2018
Q1 		$772K Buy
14,629
+14,440
+7,640% +$843K ﹤0.01% 1289
2017
Q4 		$13K Hold
189
– – ﹤0.01% 1800
2017
Q3 		$16K Hold
189
– – ﹤0.01% 1789
2017
Q2 		$18K Sell
189
-21,204
-99% -$1.3M ﹤0.01% 1775
2017
Q1 		$1.36M Buy
21,393
+21,208
+11,464% +$1.29M ﹤0.01% 1050
2016
Q4 		$8K Buy
185
+11
+6% +$387 ﹤0.01% 1782
2016
Q3 		$6K Buy
174
+13
+8% +$279 ﹤0.01% 1771
2016
Q2 		$2K Buy
161
+4
+3% +$58 ﹤0.01% 1632
2016
Q1 		$3K Buy
157
+13
+9% +$275 ﹤0.01% 1658
2015
Q4 		$5K Buy
144
+10
+7% +$645 ﹤0.01% 1674
2015
Q3 		$12K Buy
134
+13
+11% +$1.13K ﹤0.01% 1603
2015
Q2 		$11K Buy
+121
New +$10.4K ﹤0.01% 1618

Other funds holding CLVS

IFP Advisors
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $1.21B AUM 20.39% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
MAI Capital Management
MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return
Wedbush Securities
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $163M AUM 15.03% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Victory Capital Management's CLVS Position: Q4 2022 in Review

Victory Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 16,075 shares — an estimated $19K sold.

Victory Capital Management first reported a position in CLVS in Q2 2015 and held it in 25 quarters. The position peaked at $1.36M in Q1 2017. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Victory Capital Management reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Victory Capital Management sold 16,075 Clovis Oncology, Inc. shares in Q4 2022, an estimated $19K.
  • Victory Capital Management first reported a position in Clovis Oncology, Inc. in Q2 2015 and held it in 25 quarters.
  • Victory Capital Management's Clovis Oncology, Inc. position peaked at $1.36M in Q1 2017.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Victory Capital Management's 13F filing for Q4 2022, filed 9 Feb 2023.